News coverage about Ocera Therapeutics (NASDAQ:OCRX) has trended somewhat positive on Tuesday, Accern Sentiment Analysis reports. The research group scores the sentiment of press coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Ocera Therapeutics earned a news impact score of 0.17 on Accern’s scale. Accern also gave headlines about the biopharmaceutical company an impact score of 46.416259163447 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.

These are some of the news headlines that may have effected Accern Sentiment’s scoring:

OCRX has been the topic of a number of research reports. Aegis restated a “buy” rating and issued a $3.00 price target on shares of Ocera Therapeutics in a research note on Monday, April 17th. HC Wainwright restated a “buy” rating and issued a $4.00 price target on shares of Ocera Therapeutics in a research note on Wednesday, May 10th. Finally, Zacks Investment Research downgraded Ocera Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, May 17th. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $3.85.

Ocera Therapeutics (NASDAQ OCRX) opened at 1.05 on Tuesday. The stock’s market capitalization is $27.84 million. The company’s 50-day moving average price is $1.14 and its 200 day moving average price is $1.09. Ocera Therapeutics has a 52-week low of $0.52 and a 52-week high of $3.15.

Ocera Therapeutics (NASDAQ:OCRX) last posted its quarterly earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($0.23) EPS for the quarter, beating the consensus estimate of ($0.24) by $0.01. Ocera Therapeutics had a negative net margin of 4,416.26% and a negative return on equity of 175.02%. On average, equities research analysts predict that Ocera Therapeutics will post ($1.08) earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “Ocera Therapeutics (OCRX) Earns News Sentiment Score of 0.17” was reported by Watch List News and is the sole property of of Watch List News. If you are viewing this story on another site, it was copied illegally and reposted in violation of U.S. and international trademark & copyright laws. The legal version of this story can be read at

Ocera Therapeutics Company Profile

Ocera Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on acute and chronic orphan liver diseases. The Company is focused on the development and commercialization of its clinical candidate, OCR-002, for the treatment of hepatic encephalopathy (HE). OCR-002 is a molecule, ornithine phenylacetate, which functions as an ammonia scavenger.

Insider Buying and Selling by Quarter for Ocera Therapeutics (NASDAQ:OCRX)

Receive News & Ratings for Ocera Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocera Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.